Now let me do calibration searches to score this paper properly.Now I have enough to write the final review. Let me synthesize all findings.## Summary
GFMBench is an open-source benchmarking framework that integrates four pre-existing genomic benchmark suites (RGB, PGB, GUE, GB) covering 42 million sequences across 75 datasets, with unified model/tokenizer wrappers for heterogeneous GFM architectures (Transformers, Hyena, Mamba), standardized hyperparameter settings, FAIR-compliant metadata, and an automated leaderboard pipeline (AutoBench). The paper additionally reports comprehensive evaluation results for 10+ open-source GFMs across all four benchmarks, with OmniGenome—an RNA-trained model incorporating structural pretraining—achieving top-tier performance across most tasks.

---

## Strengths

- **Architecture-agnostic wrapper design (Section 2.1, "Genomic Foundation Models")**: The tokenizer and model wrapper templates that unify heterogeneous architectures (Transformer, Hyena, Mamba) and diverse tokenization strategies (k-mers, BPE, SNT) represent a genuine practical contribution. Incorrect tokenizer instantiation is a real source of performance variance in GFM comparisons, and the wrapper system addresses this concretely.

- **Standardized benchmark protocols (Section 2.1, "Benchmark Standardization")**: Freezing hyperparameters, distributing FAIR-compliant metadata, supporting custom metric implementations, and eliminating manual leaderboard submissions are all concrete engineering choices that improve reproducibility. The motivation—that Chen et al. (2020) and Fu et al. (2022) reached conflicting conclusions on E2EFold due to metric differences—is well-chosen.

- **Breadth of integration (Section 2.1, "Benchmark Suites"; Tables 1–4)**: Combining RNA (RGB), plant DNA (PGB), multi-species DNA (GUE), and regulatory-element DNA (GB) benchmarks under a single evaluation interface is broader than prior DNA-only or RNA-only benchmarks. The system supports models originally trained on either modality and cross-benchmarks them without code modification.

- **Cross-modal finding (Table 2, Section 3.2)**: The finding that OmniGenome (RNA-trained) achieves top-tier performance on DNA-based PGB tasks (87.55 F1 on PolyA, 98.41 on Splice Site) is a concrete cross-modal generalization result enabled by the framework's adaptive benchmarking capability.

- **Data leakage mitigation (Introduction)**: The paper explicitly addresses data leakage in structure prediction tasks through sequence/structure similarity filtering, a practical concern that several prior genomic benchmarks have not systematically handled.

---

## Weaknesses

### Fatal
None that fully invalidate the infrastructure contribution. However, see Major items below, which collectively undermine the paper's credibility as a *neutral* benchmarking platform.

### Major

- **Table 4 mislabeling: the framework name appears as a competitor row.** In Table 4 (GB benchmark), the final row is labeled "GFMbench" — the name of the framework itself — rather than "OmniGenome." The surrounding text (Section 3.4) then states "OmniGenome attains the highest F1 score of 82.23" for HEE, which matches exactly the value in the mislabeled row. A benchmarking paper's core credibility rests on transparent result attribution; labeling the framework as a competing model is a significant integrity issue, regardless of whether it is a copy-paste error or deliberate conflation. Every GB result reported for the top performer cannot be cleanly interpreted without knowing which model produced it.

- **Confirmed numerical inconsistency between Section 3.3 text and Table 3.** Section 3.3 states: *"For the Virus CVC task, OmniGenome also achieves the best performance with an F1 score of **74.72**."* Table 3 shows OmniGenome's Virus CVC score as **64.41** — a discrepancy exceeding 10 F1 points. This is not a rounding artifact; it is a factual error. For a paper explicitly motivated by metric reliability and reproducibility, a discrepancy of this magnitude between the results narrative and the reported table damages confidence in whether other textual claims accurately describe the actual data.

- **OmniGenome provenance and benchmark neutrality.** OmniGenome is evaluated prominently across all four benchmarks and named the top performer in virtually every section (Sections 3.1–3.5), yet it is never given a bibliographic citation, unlike every other model (DNABERT-2, HyenaDNA, Caduceus, etc.). The reference "Yang & Li (2024)" is cited for the RGB benchmark and for the finding that RNA structural pretraining improves DNA tasks — strongly suggesting this paper describes OmniGenome and shares authorship. A benchmark framework whose headline empirical result is "our own model wins" without disclosing that relationship undermines the platform's central value proposition as neutral infrastructure. Reviewers cannot assess potential evaluation bias without knowing whether the benchmark suites (task formulation, hyperparameters, evaluation protocols) were designed by the same group that trained OmniGenome.

- **EternaV2 performance gap is unexplained and potentially reflects task-formulation bias.** Table 1 shows all models except OmniGenome scoring 0–4% on EternaV2 (RNA design), while OmniGenome achieves 84%. ViennaRNA achieves 33% (the only interpretable non-zero baseline), which makes near-zero scores for all deep-learning models additionally puzzling. The paper attributes OmniGenome's advantage to "structural information" but provides no description of the interface used for each model class on this generative task, nor any explanation of why models with tens of millions of parameters score below random. If EternaV2 requires OmniGenome's structure-conditioned generation interface and other models receive a degenerate or task-inapplicable input, the result reflects task formulation rather than model capability — and should be flagged accordingly. As presented, this single task dramatically inflates OmniGenome's apparent advantage without mechanistic justification.

### Minor

- **"Data scarcity" framing overstates the contribution.** GFMBench does not generate new data; it aggregates four pre-existing benchmarks. Framing this as addressing "data scarcity" in the introduction is misleading. The actual contribution is *benchmark standardization and automation*, which is valuable but should be described accurately.

- **"Adaptive benchmarking" is conceptually described but empirically undemonstrated as a standalone contribution.** Section 2.1 defines adaptive benchmarking as running GFMs across different genomic modalities without modification. While Tables 2 and 3 contain RNA-trained models evaluated on DNA tasks, there is no dedicated analysis isolating what adaptive benchmarking *reveals* beyond what conventional benchmarking would show. The concept needs either a focused experiment or more modest framing.

- **Variance estimates absent from Tables 2, 3, and 4.** Table 1 explicitly notes results are "averaged based on five random seeds." Tables 2–4 omit this information entirely. For a paper explicitly motivated by reproducibility and metric reliability, this inconsistency is worth addressing.

- **Missing models in GUE table without explanation.** Agro-NT and 5UTRBERT appear in Tables 1 and 2 but are absent from Table 3 (GUE). Section 3.5 acknowledges some models are missing from some benchmarks but provides no explanation for these specific omissions in GUE.

### Trivial

- Conclusion section uses "GFMsBench" (with extra 's') inconsistently with the framework name used throughout the rest of the paper.

---

## Nice-to-Haves

- A per-task model ranking heatmap across all four benchmarks would reveal whether OmniGenome's dominance is uniform or concentrated in specific task types, providing actionable model-selection guidance.
- Explicit analysis of which architectural or pretraining decisions (sequence-only vs. structure-aware, RNA vs. DNA pretraining) predict cross-modal transfer success or failure — this would elevate the scientific contribution of the benchmark results section.
- A validation run comparing PGB re-implementation results against any independently reported numbers for at least one model, to demonstrate fidelity of the reimplemented protocol.

---

## Removed Points

*These points are flagged to be removed; treat them with caution.*

- **"Missing related works" (BEACON, RNABench, GenBench, DEGB dismissal too brief):** Per hard rules, absence of related work discussion cannot be evaluated without external sources to confirm paper content, and the paper does acknowledge these works exist.

- **PGB re-implementation validation as a reproducibility concern:** Removed per soft rule — demanding validation of reimplemented baselines is a reproducibility nitpick beyond what is standard for this type of infrastructure paper.

- **Strength: "42M genomic sequences addressing data scarcity"** (Strength Finder): This is weakened — GFMBench aggregates existing data, it does not create it. Promoted to a minor weakness (see above). The claim of addressing "data scarcity" is partially false.

- **Strength: "Community infrastructure / leaderboard"**: Generic software feature, not a substantive research contribution. The leaderboard is a fine engineering feature but not independently remarkable.

- **Strength: "Containerized environments for reproducibility"**: One line in Section 2.2 ("Community"), not meaningfully elaborated. Removed as insufficiently evidenced.

---

## Novel Insights

The most interesting empirically grounded finding enabled by GFMBench's cross-modal design is that RNA-pretrained models incorporating structural information (OmniGenome) outperform DNA-specialist models on several DNA-based tasks (PGB Table 2: PolyA, LncRNA, Splice Site). If the result is valid and the benchmark neutral, this suggests structural genomic pretraining provides transferable representations that transcend nucleic acid modality — a finding that prior DNA-only benchmarks could not have surfaced. However, until the provenance of OmniGenome and the EternaV2 task formulation are transparent, this insight must be treated cautiously.

---

## Suggestions

1. **Disclose OmniGenome's relationship to the authors** (or ensure a proper independent citation). Without this, the benchmark cannot function as a credible neutral evaluation resource for the community.
2. **Fix Table 4 labeling** — replace "GFMbench" row with "OmniGenome" and verify all other row labels.
3. **Correct the Section 3.3 Virus CVC claim** (74.72 → 64.41) and audit all other text-table correspondences.
4. **Provide an EternaV2 interface audit**: describe exactly how each model class interfaces with the RNA design task and why near-zero is expected for non-structure-aware models. If the task is only meaningful for OmniGenome-class models, report it separately with a disclaimer.
5. **Add variance to Tables 2–4** or explicitly note they are single-seed results.
6. **Revise "data scarcity" claims** to accurately describe the contribution as benchmark *standardization and aggregation*, not new data generation.

---

## Score and Decision

**Calibration anchors used:**

| Path | Avg Score | Decision | Comparison |
|------|-----------|----------|-----------|
| `0bswm093Yl.md` (GeneBench) | 4.75 | Withdrawn/Reject | Near-identical contribution (GFM benchmarking framework + evaluation results); GeneBench had fewer confirmed factual errors and no mislabeling issues |
| `fopjVghcE2.md` (DGEB) | 5.50 | Reject | Genomic benchmarking paper; stronger on biological task curation, weaker on automation; similarly rejected |
| `8O9HLDrmtq.md` (Genomics LRB) | 5.00 | Reject | DNA LM benchmarking, narrower scope, fewer integrity issues but also rejected |
| `oMLQB4EZE1.md` (DNABERT-2 + GUE) | 6.50 | Accept | Model + benchmark, genuine novel model contribution (BPE tokenization), comprehensive clean results; stronger than GFMBench |

**Assessment relative to anchors:** GFMBench is topically closest to GeneBench (avg 4.75) and has a materially worse integrity profile — two confirmed factual errors (table mislabeling, text-table numerical discrepancy), an unexplained 20× EternaV2 gap, and a structurally undisclosed self-promotional relationship with OmniGenome. These issues go beyond presentation to affect the foundational credibility of the benchmark's neutrality claim. The infrastructure contribution (multi-architecture wrappers, standardized protocols) is genuine but provides insufficient scientific novelty on its own, particularly when the benchmark's claimed headlining result cannot be cleanly attributed. GeneBench scored 4.75 and was rejected despite being cleaner; GFMBench should score below that level.

**Final Score: 4.0 — Reject**

The infrastructure contribution is real and the benchmarking gap in genomics is genuine, but the paper cannot be accepted in its current form. The Table 4 mislabeling, confirmed Section 3.3 numerical error, undisclosed relationship between GFMBench and OmniGenome, and unexplained EternaV2 collapse collectively undermine the benchmark's credibility as a neutral evaluation platform — the single most important property a benchmarking paper must have.

**Originality**: Low-to-moderate — primarily re-implementation and aggregation of existing benchmarks with automation tooling.
**Importance of research question**: High — standardized GFM benchmarking is genuinely needed.
**Claims supported by experiments**: Poor — confirmed text-table discrepancies, unexplained outlier results, no ablation supporting "adaptive benchmarking" as a distinct contribution.
**Soundness of experiments**: Questionable — integrity issues in reporting undermine confidence in other numbers.
**Clarity of writing**: Below average — confirmed factual errors, inconsistent terminology.
**Value to community**: Moderate if corrected — the software infrastructure would be useful if the integrity issues are resolved.

MY FINAL SCORE: <pineapple>4.0</pineapple>
MY FINAL DECISION: <orange>Reject</orange>